To gain further understanding of the impact of FADS1 and FADS2 on R/R AML metabolism, we performed 13C6-glucose metabolic tracing and observed alterations in glycolytic and TCA cycle metabolism upon pharmacologic FADS1 and FADS2 inhibition. This evidence concerns the gene FADS1 and acute myeloid leukemia.